Esperion Therapeutics (ESPR)
(Real Time Quote from BATS)
$1.79 USD
+0.17 (10.49%)
Updated Aug 6, 2025 02:40 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Esperion Therapeutics, Inc. has a market cap of $321.08M, which represents its share price of $1.62 multiplied by its outstanding shares number of 198.20M. As a small-cap company, ESPR's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ESPR 1.79 +0.17(10.49%)
Will ESPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Other News for ESPR
Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ...
Esperion Therapeutics (ESPR) Sees Revenue Surge, Eyes Profitability by 2026
Q2 2025 Esperion Therapeutics Inc Earnings Call Transcript
Esperion rises after revenue beat, Q1 profitability expectation
Esperion expects sustainable profitability in Q1 2026 as double-digit growth continues